Search Results - "SADOWSKY, Carl H"

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study by Clark, Christopher M, MD, Pontecorvo, Michael J, Dr, Beach, Thomas G, MD, Bedell, Barry J, MD, Coleman, R Edward, Prof, Doraiswamy, P Murali, Prof, Fleisher, Adam S, MD, Reiman, Eric M, Prof, Sabbagh, Marwan N, MD, Sadowsky, Carl H, Prof, Schneider, Julie A, MD, Arora, Anupa, MD, Carpenter, Alan P, PhD, Flitter, Matthew L, BA, Joshi, Abhinay D, MS, Krautkramer, Michael J, BS, Lu, Ming, MS, Mintun, Mark A, MD, Skovronsky, Daniel M, MD

“…Summary Background Results of previous studies have shown associations between PET imaging of amyloid plaques and amyloid-β pathology measured at autopsy…”
Get full text

Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease by Fleisher, Adam S, Chen, Kewei, Liu, Xiaofen, Ayutyanont, Napatkamon, Roontiva, Auttawut, Thiyyagura, Pradeep, Protas, Hillary, Joshi, Abhinay D, Sabbagh, Marwan, Sadowsky, Carl H, Sperling, Reisa A, Clark, Christopher M, Mintun, Mark A, Pontecorvo, Michael J, Coleman, R. Edward, Doraiswamy, P.M, Johnson, Keith A, Carpenter, Alan P, Skovronsky, Daniel M, Reiman, Eric M

“…Abstract Objectives Investigate apolipoprotein E ε4 (APOE4) gene and aging effects on florbetapir F18 positron emission tomography (PET) in normal aging and…”
Get full text

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging by Johnson, Keith A, Sperling, Reisa A, Gidicsin, Christopher M, Carmasin, Jeremy S, Maye, Jacqueline E, Coleman, Ralph E, Reiman, Eric M, Sabbagh, Marwan N, Sadowsky, Carl H, Fleisher, Adam S, Murali Doraiswamy, P, Carpenter, Alan P, Clark, Christopher M, Joshi, Abhinay D, Lu, Ming, Grundman, Michel, Mintun, Mark A, Pontecorvo, Michel J, Skovronsky, Daniel M

“…Abstract Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD),…”
Get full text

Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects by Joshi, Abhinay D, Pontecorvo, Michael J, Clark, Chrisopher M, Carpenter, Alan P, Jennings, Danna L, Sadowsky, Carl H, Adler, Lee P, Kovnat, Karel D, Seibyl, John P, Arora, Anupa, Saha, Krishnendu, Burns, Jason D, Lowrey, Mark J, Mintun, Mark A, Skovronsky, Daniel M

“…The objectives of this study were to examine the effective dose range and the test-retest reliability of florbetapir F 18 using, first, visual assessment by…”
Get full text

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density by Curtis, Craig, Gamez, Jose E, Singh, Upinder, Sadowsky, Carl H, Villena, Teresa, Sabbagh, Marwan N, Beach, Thomas G, Duara, Ranjan, Fleisher, Adam S, Frey, Kirk A, Walker, Zuzana, Hunjan, Arvinder, Holmes, Clive, Escovar, Yavir M, Vera, Carla X, Agronin, Marc E, Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D, Sherwin, Paul F, Grachev, Igor D, Farrar, Gillian, Smith, Adrian P L, Buckley, Christopher J, McLain, Richard, Salloway, Stephen

“…In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the…”
Get more information

Use of Florbetapir-PET for Imaging β-Amyloid Pathology by Clark, Christopher M, Schneider, Julie A, Bedell, Barry J, Beach, Thomas G, Bilker, Warren B, Mintun, Mark A, Pontecorvo, Michael J, Hefti, Franz, Carpenter, Alan P, Flitter, Matthew L, Krautkramer, Michael J, Kung, Hank F, Coleman, R. Edward, Doraiswamy, P. Murali, Fleisher, Adam S, Sabbagh, Marwan N, Sadowsky, Carl H, Reiman, Eric M, Zehntner, Simone P, Skovronsky, Daniel M, AV45-A07 Study Group, for the

“…CONTEXT The ability to identify and quantify brain β-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease. OBJECTIVE To determine…”
Get full text

Switching from Donepezil Tablets to Rivastigmine Transdermal Patch in Alzheimer's Disease by Sadowsky, Carl H., Dengiz, Alan, Olin, Jason T., Koumaras, Barbara, Meng, Xiangyi, Brannan, Stephen

“…Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer's…”
Get full text

Practical guidelines for the recognition and diagnosis of dementia by Galvin, James E, Sadowsky, Carl H

“…To date, user-friendly, practical guidelines for dementia have not been available for busy family physicians. However, the growing number of patients with…”
Get full text

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study by MURALI DORAISWAMY, P, SPERLING, Reisa A, CARPENTER, Alan, CLARK, Christopher M, JOSHI, Abhinay D, MINTUN, Mark A, SKOVRONSKY, Daniel M, PONTECORVO, Michael J, COLEMAN, R. Edward, JOHNSON, Keith A, REIMAN, Eric M, DAVIS, Mat D, GRUNDMAN, Michael, SABBAGH, Marwan N, SADOWSKY, Carl H, FLEISHER, Adam S

“…Florbetapir F 18 PET can image amyloid-β (Aβ) aggregates in the brains of living subjects. We prospectively evaluated the prognostic utility of detecting Aβ…”
Get full text

Guidelines for the management of cognitive and behavioral problems in dementia by Sadowsky, Carl H, Galvin, James E

“…Family physicians play a crucial role in the management and ongoing care of patients with Alzheimer disease (AD). This article reviews the effects of…”
Get full text

Amyloid deposition detected with florbetapir F 18 (18 F-AV-45) is related to lower episodic memory performance in clinically normal older individuals by Sperling, Reisa A, Johnson, Keith A, Doraiswamy, P. Murali, Reiman, Eric M, Fleisher, Adam S, Sabbagh, Marwan N, Sadowsky, Carl H, Carpenter, Alan, Davis, Mat D, Lu, Ming, Flitter, Matthew, Joshi, Abhinay D, Clark, Christopher M, Grundman, Michael, Mintun, Mark A, Skovronsky, Daniel M, Pontecorvo, Michael J

“…Abstract The objective of this study was to evaluate the relationship of amyloid burden, as assessed by florbetapir F 18 (18 F-AV-45) amyloid positron emission…”
Get full text

A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia by Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique

“…Summary Aims The 24‐week, prospective, randomized, double‐blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h…”
Get full text

Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline by GRUNDMAN, Michael, PONTECORVO, Michael J, AGBULOS, Abigail, FLITTER, Matthew L, KRAUTKRAMER, Michael J, SARSOUR, Khaled, SKOVRONSKY, Daniel M, MINTUN, Mark A, SALLOWAY, Stephen P, MURALI DORAISWAMY, P, FLEISHER, Adam S, SADOWSKY, Carl H, NAIR, Anil K, SIDEROWF, Andrew, MING LU, ARORA, Anupa K

“…Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for…”
Get full text

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease by Shah, Raj C, Kamphuis, Patrick J, Leurgans, Sue, Swinkels, Sophie H, Sadowsky, Carl H, Bongers, Anke, Rappaport, Stephen A, Quinn, Joseph F, Wieggers, Rico L, Scheltens, Philip, Bennett, David A

“…Souvenaid® containing Fortasyn® Connect is a medical food designed to support synapse synthesis in persons with Alzheimer's disease (AD). Fortasyn Connect…”
Get full text

Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer’s Disease by Kerbage, Charles, Sadowsky, Carl H., Tariot, Pierre N., Agronin, Marc, Alva, Gustavo, Turner, F. Darell, Nilan, Dennis, Cameron, Anne, Cagle, Gerald D., Hartung, Paul D.

“…We report the findings from a clinical trial in which a group of patients clinically diagnosed with probable Alzheimer’s disease (AD) were discriminated from…”
Get full text

Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease by Salloway, Stephen, Gamez, Jose E., Singh, Upinder, Sadowsky, Carl H., Villena, Teresa, Sabbagh, Marwan N., Beach, Thomas G., Duara, Ranjan, Fleisher, Adam S., Frey, Kirk A., Walker, Zuzana, Hunjan, Arvinder, Escovar, Yavir M., Agronin, Marc E., Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D., Sherwin, Paul F., Farrar, Gill, Smith, Adrian P.L., Buckley, Christopher J., Thal, Dietmar Rudolf, Zanette, Michelle, Curtis, Craig

“…Performance of the amyloid tracer [18F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD…”
Get full text

A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings by Cecchi, Marco, Moore, Dennis K, Sadowsky, Carl H, Solomon, Paul R, Doraiswamy, P. Murali, Smith, Charles D, Jicha, Gregory A, Budson, Andrew E, Arnold, Steven E, Fadem, Kalford C

“…Abstract Introduction We investigated whether event-related potentials (ERP) collected in outpatient settings and analyzed with standardized methods can…”
Get full text

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease by Farlow, Martin R, Grossberg, George T, Sadowsky, Carl H, Meng, Xiangyi, Velting, Drew M

“…The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week,…”
Get full text

Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease by Lenz, Robert A, Pritchett, Yili L, Berry, Scott M, Llano, Daniel A, Han, Shu, Berry, Donald A, Sadowsky, Carl H, Abi-Saab, Walid M, Saltarelli, Mario D

“…ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving…”
Get full text

Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates by Dugger, Brittany N, Clark, Christopher M, Serrano, Geidy, Mariner, Monica, Bedell, Barry J, Coleman, R Edward, Doraiswamy, P Murali, Lu, Ming, Fleisher, Adam S, Reiman, Eric M, Sabbagh, Marwan N, Sadowsky, Carl H, Schneider, Julie A, Zehntner, Simone P, Carpenter, Alan P, Joshi, Abhinay D, Mintun, Mark A, Pontecorvo, Michael J, Skovronsky, Daniel M, Sue, Lucia I, Beach, Thomas G

“…ABSTRACTNeuropathologic heterogeneity is often present among Alzheimer disease (AD) patients. We sought to determine whether amyloid imaging measures of AD are…”
Get full text